These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20701957)

  • 61. Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review.
    Chao WT; Liu CH; Lai CR; Chen YJ; Chuang CM; Wang PH
    J Ovarian Res; 2018 Jun; 11(1):52. PubMed ID: 29933751
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Expression of glypican 3 (GPC3) in embryonal tumors.
    Saikali Z; Sinnett D
    Int J Cancer; 2000 Sep; 89(5):418-22. PubMed ID: 11008203
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance.
    He Y; Wu AC; Harrington BS; Davies CM; Wallace SJ; Adams MN; Palmer JS; Roche DK; Hollier BG; Westbrook TF; Hamidi H; Konecny GE; Winterhoff B; Chetty NP; Crandon AJ; Oliveira NB; Shannon CM; Tinker AV; Gilks CB; Coward JI; Lumley JW; Perrin LC; Armes JE; Hooper JD
    Oncogene; 2016 Jan; 35(4):468-78. PubMed ID: 25893298
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation.
    Stigliano I; Puricelli L; Filmus J; Sogayar MC; Bal de Kier Joffé E; Peters MG
    Breast Cancer Res Treat; 2009 Mar; 114(2):251-62. PubMed ID: 18404367
    [TBL] [Abstract][Full Text] [Related]  

  • 65. LRP1 mediates Hedgehog-induced endocytosis of the GPC3-Hedgehog complex.
    Capurro MI; Shi W; Filmus J
    J Cell Sci; 2012 Jul; 125(Pt 14):3380-9. PubMed ID: 22467855
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
    Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
    Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma.
    Maeda D; Chen X; Guan B; Nakagawa S; Yano T; Taketani Y; Fukayama M; Wang TL; Shih IeM
    Int J Gynecol Pathol; 2011 Jan; 30(1):30-5. PubMed ID: 21131837
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
    Kim A; Serada S; Enomoto T; Naka T
    Expert Opin Ther Targets; 2010 Sep; 14(9):963-71. PubMed ID: 20673185
    [TBL] [Abstract][Full Text] [Related]  

  • 69. CACNA1H restrains chemotherapy resistance in ovarian clear cell carcinoma cells by repressing autophagy.
    Shi H; Zheng L; Jiang X; Chen H
    Mol Genet Genomics; 2024 Aug; 299(1):77. PubMed ID: 39105964
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary.
    Miyake R; Yamanaka S; Matsubara S; Mabuchi S
    Anticancer Res; 2021 Sep; 41(9):4277-4285. PubMed ID: 34475047
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
    Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
    J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.
    Sato S; Itamochi H; Oumi N; Chiba Y; Oishi T; Shimada M; Sato S; Chikumi J; Nonaka M; Kudoh A; Komatsu H; Harada T; Sugiyama T
    Hum Cell; 2016 Oct; 29(4):181-7. PubMed ID: 26960408
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.
    Itamochi H; Kato M; Nishimura M; Oumi N; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Nonaka M; Kudoh A; Terakawa N; Kigawa J; Harada T
    Hum Cell; 2013 Sep; 26(3):121-7. PubMed ID: 23430509
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Signaling network involved in the GPC3-induced inhibition of breast cancer progression: role of canonical Wnt pathway.
    Fernández D; Guereño M; Lago Huvelle MA; Cercato M; Peters MG
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2399-2418. PubMed ID: 30267212
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation.
    Liu B; Paranjpe S; Bowen WC; Bell AW; Luo JH; Yu YP; Mars WM; Michalopoulos GK
    Am J Pathol; 2009 Aug; 175(2):717-24. PubMed ID: 19574424
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hyalinized stroma in clear cell carcinoma of the ovary: how is it formed?
    Kato N; Takeda J; Fukase M; Motoyama T
    Hum Pathol; 2012 Nov; 43(11):2041-6. PubMed ID: 22607701
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database.
    Moek KL; Fehrmann RSN; van der Vegt B; de Vries EGE; de Groot DJA
    Am J Pathol; 2018 Sep; 188(9):1973-1981. PubMed ID: 29935166
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Processing by convertases is required for glypican-3-induced inhibition of Hedgehog signaling.
    Capurro M; Shi W; Izumikawa T; Kitagawa H; Filmus J
    J Biol Chem; 2015 Mar; 290(12):7576-85. PubMed ID: 25653284
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Glypican-3 Enhances Reprogramming of Glucose Metabolism in Liver Cancer Cells.
    Yao G; Yin J; Wang Q; Dong R; Lu J
    Biomed Res Int; 2019; 2019():2560650. PubMed ID: 31781603
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10.
    Cheng W; Huang PC; Chao HM; Jeng YM; Hsu HC; Pan HW; Hwu WL; Lee YM
    Oncotarget; 2017 Oct; 8(46):80429-80442. PubMed ID: 29113314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.